Biosimilars Development In EU Could Get Easier; EC Mulls Accepting Outside Data
Executive Summary
Industry applauds a suggestion by a senior healthcare representative that the European Commission could re-examine the overarching guideline on biosimilars to promote global development, but growth ultimately will be determined by greater worldwide harmonization.
You may also be interested in...
EU Acceptance Of Foreign Comparators For Biosimilar Applications Will Boost Industry
The European Union has announced that it will accept a reference product for a biosimilar application from countries with robust regulatory systems and similar guidelines, a move that should significantly boost the domestic biosimilars industry.
Merck Serono Biosimilars Head Thierry Hulot On Minimizing Risks And Upfront Costs: An Interview With PharmAsia News
Merck Serono is hopeful of capitalizing on the gaps existing in access for lifesaving oncology biosimilars
Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
Sales of Europe's first round of biosimilars have been poor, prompting some to suggest they're dead before they really got started. Others claim biosimilars' true value will come with the next wave: biosimilar antibodies.